Abstract:Many cancers evade immune surveillance by overexpressing PD-L1. PD-L1 interacted with its receptor PD-1, resulting in reduction of T cell proliferation and activation and thereafter cancer cell death mediated by T-lymphocyte. Understanding the mechanisms that regulate PD-L1 was of vital importance for immune checkpoint blockade therapy (ICBT). Human non-small cell lung cancer cells and 293FT cells were used to investigate the function of USP22 upon PD-L1 and CSN5 by WB, Immunoprecipitation, Immunofluorescence and Flow cytometry analysis. B16-F10 cells were used to explore the role of USP22 on tumorigenesis and T cell cytotoxicity. The relationship between USP22 and PD-L1 expression was investigated by Immunohistochemistry analysis in human non-small cell lung cancer samples. Our data showed that USP22 interacted with PD-L1 and promoted its stability. USP22 deubiquitinated PD-L1 and inhibited its proteasome degradation. Moreover, USP22 also interacted with CSN5 and stabilized CSN5 through deubiquitination. Either USP22 or CSN5 could facilitate the interaction of PD-L1 with the other one. Furthermore, USP22 removed K6, K11, K27, K29, K33 and K63-linked ubiquitin chain of both CSN5 and PD-L1. In addition, USP22 depletion inhibited tumorigenesis and promoted T cell cytotoxicity. Besides, USP22 expression positively correlated with PD-L1 expression in human non-small cell lung cancer samples. Here, we suggested that USP22 is a new regulator for PD-L1. On the one hand, USP22 could directly regulate PD-L1 stability through deubiquitination. On the other hand, USP22 regulated PD-L1 protein level through USP22-CSN5-PD-L1 axis. In addition, USP22 depletion inhibited tumorigenesis and promoted T cell cytotoxicity. Besides, USP22 expression positively correlated with PD-L1 expression in human non-small cell lung cancer samples. Together, we identified a new regulator of PD-L1 and characterized the important role of USP22 in PD-L1 mediated immune evasion. Targeting USP22 might be a new solution to ICBT.

Deubiquitinase USP33 is Negatively Regulated by Β-Trcp Through Ubiquitin-Dependent Proteolysis.

Ubiquitin specific peptidase 3: an emerging deubiquitinase that regulates physiology and diseases

USP10 Regulates p53 Localization and Stability by Deubiquitinating p53

Domain Analysis Reveals That a Deubiquitinating Enzyme USP13 Performs Non-Activating Catalysis for Lys63-linked Polyubiquitin.

USP39 Regulates DNA Damage Response and Chemo-Radiation Resistance by Deubiquitinating and Stabilizing CHK2.

The Deubiquitinating Enzyme USP4 Regulates BRCA1 Stability and Function

Deubiquitinating Enzyme USP33 Restrains Docetaxel-Induced Apoptosis Via Stabilising the Phosphatase DUSP1 in Prostate Cancer

USP11 regulates p53 stability by deubiquitinating p53.

USP3: Key deubiquitylation enzyme in human diseases

USP47-Mediated Deubiquitination and Stabilization of TCEA3 Attenuates Pyroptosis and Apoptosis of Colorectal Cancer Cells Induced by Chemotherapeutic Doxorubicin.

Ubiquitin-specific protease 25 regulates TLR4-dependent innate immune responses through deubiquitination of the adaptor protein TRAF3.

USP33 enhances cell survival and stemness by deubiquitinating CTNNB1 in BXPC-3 and SW1990 cells

USP33 facilitates the ovarian cancer progression via deubiquitinating and stabilizing CBX2

The Deubiquitinase USP22 Regulates PD-L1 Degradation in Human Cancer Cells.

USP13 Antagonizes Gp78 to Maintain Functionality of a Chaperone in ER-associated Degradation

USP2 is an SKP2 Deubiquitylase That Stabilizes Both SKP2 and Its Substrates

Structure and Function of the Highly Homologous Deubiquitinases Ubiquitin Specific Peptidase 25 and 28: Insights into Their Pathophysiological and Therapeutic Roles.

USP33 promotes pancreatic cancer malignant phenotype through the regulation of TGFBR2/TGFβ signaling pathway

Deubiquitylation and stabilization of PTEN by USP13

Regulation of TLR-triggered Innate Immune Response by Ubiquitin-Specific Protease 25 (180.8)

Ubiquitin specific peptidase 33 promotes cell proliferation and reduces apoptosis through regulation of the SP1/PI3K/AKT pathway in retinoblastoma